Contents
Special Issue Topic

Innovative Strategies to Target Triple-negative Breast Cancer

Submission Deadline: May 31, 2023

Guest Editors

Dr. Laura Cerchia E-Mail

Institute of Experimental Endocrinology and Oncology

Research Keywords: RNA aptamer; SELEX technology; targeted therapy; targeted drug delivery; cancer theranostics; cancer cell biology and signaling; TNBC

Dr. Simona Camorani E-Mail

Institute of Experimental Endocrinology and Oncology

Research Keywords: Triple-negative breast cancer; RNA aptamers; cell-SELEX technology; cancer cell biology and signaling; targeted therapy; targeted delivery system; chemotherapy resistance; cancer immunotherapy

About the Special lssue

Triple-negative breast cancer (TNBC), which represents approximately 15-20% of all diagnosed breast cancers, has a distinctly aggressive nature, high risk for recurrence and poor prognosis. TNBC lacks expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2), thus TNBC patients are not eligible for hormone or anti-HER2 therapies. Neoadjuvant chemotherapy is the standard of care for many TNBC patients but about 30-50% develop resistance. While the overall mortality for breast cancer has recently declined, management of TNBC is still challenging because of its high biological/clinical heterogeneity and the limited targeted therapies that are available for restricted groups of patients. These include: 1) PARP inhibitors (Olaparib or Talazoparib) for BRCA-mutated patients; 2) anti-PD-L1 (Atezolizumab) or anti-PD-1 (Pembrolizumab) monoclonal antibodies, in combination with chemotherapy, for patients with unresectable locally advanced or metastatic PD-L1-positive TNBC and 3) the antibody-drug conjugate (Sacituzumab govitecan), recently approved for patients with metastatic TNBC expressing anti-trophoblast cell-surface antigen.

TNBC has an urgent therapeutic need. This Special Issue invites original research articles and timely reviews on all aspects regarding innovative strategies to target triple-negative breast cancer, highlighting problems, solutions and future directions in the development of new therapeutic approaches.

Keywords: Molecular heterogeneity; tumor microenvironment; novel targets; active cancer targeting; mechanisms of drug resistance; immunotherapy and combination treatments; antibody-based therapeutics; aptamer-based targeted therapies

Published Articles

Open Access Original Article
Hexachlorobenzene as a differential modulator of the conventional and metronomic chemotherapy response in triple negative breast cancer cells
Yamila Sanchez ... Alejandro Español
Published: March 21, 2024 Explor Target Antitumor Ther. 2024;5:278–295
1455 28 1
Open Access Review
Early-stage triple negative breast cancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response
Pierluigi De Santis ... Palma Fedele
Published: February 28, 2024 Explor Target Antitumor Ther. 2024;5:232–250
8317 188 1
Open Access Original Article
Efficacy of metformin and electrical pulses in breast cancer MDA-MB-231 cells
Praveen Sahu ... Raji Sundararajan
Published: February 19, 2024 Explor Target Antitumor Ther. 2024;5:54–73
1809 22 5
Open Access Original Article
Identification of lysyl oxidase as an adipocyte-secreted mediator that promotes a partial mesenchymal-to-epithelial transition in MDA-MB-231 cells
Cassidy M. Van Stiphout ... Alicia M. Viloria-Petit
Published: January 16, 2024 Explor Target Antitumor Ther. 2024;5:1–19
1818 25 1
Open Access Perspective
Facing the conundrum: which first-line therapy should be used for patients with metastatic triple-negative breast cancer carrying germline BRCA mutation?
Sabah Alaklabi ... Shipra Gandhi
Published: December 27, 2023 Explor Target Antitumor Ther. 2023;4:1301–1309
1852 23 0
Open Access Review
Targeting cancer stem cell plasticity in triple-negative breast cancer
Zhengwang Guo, Shuyan Han
Published: December 11, 2023 Explor Target Antitumor Ther. 2023;4:1165–1181
2209 30 2
Open Access Review
Nuclear epidermal growth factor receptor as a therapeutic target
Benjamin Atwell ... Joyce Schroeder
Published: August 30, 2023 Explor Target Antitumor Ther. 2023;4:616–629
1877 35 3